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Behavioral studies have suggested that placebo analgesia is partlymediated by the endogenous opioid sys-
tem. Expanding on these resultswehave shown that the opioid-receptor-rich rostral anterior cingulate cor-
tex (rACC) is activated in both placebo and opioid analgesia. However, there are also differences between
the two treatments. While opioids have direct pharmacological effects, acting on the descending pain
inhibitory system, placebo analgesia depends on neocortical top-down mechanisms. An important differ-
ence may be that expectations are met to a lesser extent in placebo treatment as compared with a speciﬁc
treatment, yielding a larger error signal. As these processes previously have been shown to inﬂuence other
types of perceptual experiences, we hypothesized that they also may drive placebo analgesia. Imaging
studies suggest that lateral orbitofrontal cortex (lObfc) and ventrolateral prefrontal cortex (vlPFC) are
involved in processing expectation and error signals. We re-analyzed two independent functional imaging
experiments related to placebo analgesia and emotional placebo to probe for a differential processing in
these regions during placebo treatment vs. opioid treatment and to test if this activity is associated with
the placebo response. In the ﬁrst dataset lObfc and vlPFC showed an enhanced activation in placebo anal-
gesia vs. opioid analgesia. Furthermore, the rACC activity co-varied with the prefrontal regions in the pla-
cebo condition speciﬁcally. A similar correlation between rACC and vlPFC was reproduced in another
dataset involving emotional placebo and correlated with the degree of the placebo effect. Our results thus
support that placebo is different from speciﬁc treatment with a prefrontal top-down inﬂuence on rACC.
 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.1. Introduction
It is widely accepted that placebo analgesia is mediated by the
endogenous opioid system since the opioid receptor antagonist
naloxone attenuates the placebo effect [2,5–7,26]. In line with this
we have shown a similar functional anatomy of opioid and placebo
analgesia [34]. Opioid-rich regions including the rostral anterior
cingulate cortex (rACC) were involved in both conditions. Our ini-
tial ﬁndings have been replicated and extended [8,21,51,52,58]. In
a recent functional MRI (fMRI) study, we generalized our previous
results on placebo analgesia [34] to emotional processing which
showed a similar pattern of placebo-dependent activation [36].
Opioid analgesia is mediated through a direct pharmacological
activation of the endogenous opioid receptors and shares the prop-for the Study of Pain. Published by
N8, Department of Clinical
kholm, Sweden. Tel.: +46
.petrovic@cns.ki.se (P. Petro-erties of a placebo manipulation initially. However, differences in
the cerebral processing would be expected during ongoing treat-
ment especially in terms of expectation and error signals – pro-
cesses that have shown to profoundly modulate visual perception
and emotional experiences [17,28,44,57]. In the opioid condition,
expectations for effective analgesia are met and therefore remain
congruent with the level of nociceptive processing. On the other
hand, in the placebo condition, the treatment expectation is upheld
by means of the placebo manipulation that is incongruent with
processing level of the nociceptive input. Potentially, this would re-
sult in an error signal between the expectations and the nocicep-
tive processing. The expression of such an error signal in pain
processing has been demonstrated by means of deliberate manip-
ulations of the expected intensity of pain [43] where the error sig-
nal correlated with an increased activity in the lateral orbitofrontal
cortices. An important question is whether expectations and error
processing directly relate to placebo analgesia as has been indi-
cated in other perceptual experiences and emotion [17,28,44,57].
Behavioral results indicate such a relationship as the level of expli-
cit expectation has been shown to correlate to the subsequently re-
ported pain level [39].Elsevier B.V. All rights reserved.
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150 (2010) 59–65Orbitofrontal- and ventrolateral prefrontal cortex have been
suggested to be involved in higher order emotional and pain regu-
lations [32,35] including placebo analgesia [21,27,34,51], and error
and expectation processings [18,31,43]. However, these regions do
not show a clear opioid receptor binding or opioid-induced activa-
tion in functional imaging studies [10,15,19,34,53,55,56]. In the
present study we hypothesized that the prefrontal regions code
for the expected nociceptive processing and error signals, which
then inﬂuence the descending opioid system in the ACC speciﬁcally
during placebo analgesia. In that case, the prefrontal activity and
the interaction with the ACC should be more pronounced in the
placebo condition than in the opioid condition. Moreover, the func-
tional relation between the prefrontal regions and ACC should cor-
relate with the reported placebo effect. To test this suggestion we
re-analyzed the dataset from our previous placebo analgesia PET
study [34] and emotional placebo fMRI study [36].Fig. 1. The ROIs in the rACC used for the functional connectivity analysis are shown
in the SPM-template below. In Study 1 the ROI was focused on the region showing
the most expressed activations in the rACC after opioid treatment
([X Y Z] = [8 44 12]). In Study 2 the ROI was focused on the most expressed
placebo-induced activation in the placebo responders after controlling for unspe-
ciﬁc placebo effects ([X Y Z] = [12 48 12]).2. Methods
The data presented here represent a re-analysis of the two pre-
viously presented materials [34,36]. The re-analysis involves new
contrast and functional connectivity analyses.
2.1. Study 1 – PET study on placebo and opioid analgesia
The ﬁrst study focused on placebo and opioid analgesia [34]. In
this positron emission tomography (PET) study on the placebo
analgesia effect nine healthy male subjects participated (age: 20–
27 years). Most of the results have been presented in a previous
article [34].
In the present analysis two conditions were further compared:
(1) pain and opioid treatment, i.e. opioid analgesia (POP) and (2)
pain and placebo treatment, i.e. placebo analgesia (PPL). In both
conditions the subjects had been stimulated with a tonic noxious
heat stimulation (48 C, 70 s, stimulation area = 2  3 cm) on the
dorsum of the left hand. In the POP condition the subjects had been
pre-treated with a short-lasting opioid (remifentanil 0.5 lg/kg)
intravenously. In the PPL condition the subjects had been given sal-
ine intravenously but they assumed that a strong analgesic was
administered. Both treatments were given in a double blind fash-
ion. Both conditions had been performed twice in each subject.
For more detailed methods see [34]. For completeness we also
modeled the other original conditions in the present re-analysis
(Pain stimulation only – P; Warm stimulation and opioid treatment
– WOP; Warm stimulation and placebo treatment – WPL; Warm
stimulation only – W). However, since these conditions are not a
part of the present analysis we will not discuss them further.
In the present re-analysis we used SPM99 (http://www.ﬁl.ion.u-
cl.ac.uk/spm) for pre-processing and statistical analysis of the data.
A ﬁxed-effect approach was used for the PET analysis as in the ori-
ginal analysis, i.e. each data point represents a measurement (two
for each subject). All conditions (POP, PPL, P, WOP, WPL and W)
were entered in the model as in the original analysis. We chose
not to re-analyze the dataset in a random effect model since the
power was too low due to the limited sample size in the original
PET study. The result has therefore an inference only on a group le-
vel (i.e. the results are valid for the group of individuals that took
part in the study) and not on a population level. A subtraction anal-
ysis was performed to test for differences between the PPL and the
POP conditions, i.e. (PPL–POP) and (POP–PPL). For the contrast
PPL–POP an exclusive masking procedure was implemented so
that all activations induced by general decreases in the opioid con-
dition vs. the pain condition (i.e. P–POP) with a threshold of P-
uncorrected = 0.05 were removed. This procedure indicates that
the remaining ﬁndings in PPL–POP could be attributed to increasedactivity in the PPL condition and not decreased activity in the POP
condition. A threshold of P-value (uncorrected) < 0.001 was set for
reporting results in rACC and vlPFC/Obfc since our hypothesis in-
volved speciﬁcally these regions. We also report when the activity
is bordering another region such as anterior insula.
In the present re-analysis we also performed a functional con-
nectivity analysis between the rACC and the vlPFC/lObfc in the pla-
cebo (PPL) and the opioid (POP) conditions. In the voxel showing
the highest Z-value in the rACC during the main effect of opioids
[X Y Z] = [8 44 12] the adjusted activity was extracted from all con-
ditions (Fig. 1). The adjusted activity for each scan was used as a
covariate of interest for each condition in a general linear model
and the conditions were modeled as confounding covariates. We
then studied the regressions between the rACC and the vlPFC/lObfc
during the placebo (PPL) and the opioid (POP) conditions. In addi-
tion, differences in the observed regressions between the condi-
tions were studied by employing a simple contrast analysis in
SPM99.
2.2. Study 2 – fMRI study on emotional placebo
In the second study, the placebo effect was probed during emo-
tional processing by giving a non-speciﬁc treatment that subjects
believed was an effective anxiolytic substance before presentation
of unpleasant pictures [36]. In this functional magnetic resonance
imaging (fMRI) study on emotional placebo effect 15 healthy fe-
male subjects participated (age: 20–33). On day 1 (expectation
induction) the subjects watched three blocks of unpleasant and
neutral pictures (13 unpleasant and 13 neutral pictures; stimulus
duration was 4 s; inter-stimulus interval was 7 s). The experience
of unpleasantness was lowered after the subjects received a small
intravenous dose of anxiolytic (midazolam 0.015 mg/kg) but re-
versed after they received a blocker of the anxiolytic drug (ﬂu-
mazenil 0.25 mg). This way we induced treatment expectations
that the anxiolytic drug was highly effective in reducing unpleas-
antness. On day 2 (placebo testing) the subjects were scanned in
a 1.5-T scanner while they watched similar pictures (each block
contained 10 unpleasant and 10 neutral pictures; stimulus dura-
tion was 4 s; inter-stimulus interval was jittered but 12.2 s in aver-
age). In some blocks the subjects thought that they had received
the anxiolytic drug (but had actually only received saline intrave-
nously) and rated the negative pictures as less unpleasant than
when they believed that they had received the anxiolytic blocker.
Thus, in some blocks a placebo effect had been accomplished
Table 1
Regions activated more by opioid (remifentanil 0.5 lg/kg) than by placebo during
pain (Study 1). In the present analysis a ﬁxed effect design was used.
Region MNI coordinates t-value P-value
X Y Z
Opioid analgesia vs. placebo analgesia (POP–PPL)
rACC (BA 24) 6 52 10 4.95 <0.001
Subgenual ACC/mObfc 0 22 14 3.48 <0.001
Right anterior insula/lObfc 50 10 2 4.80 <0.001
Left anterior insula/lObfc 46 4 2 5.23 <0.001
(r)ACC, (rostral) anterior cingulate cortex; mObfc, medial orbitofrontal cortex;
lObfc, lateral orbitofrontal cortex.
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(control condition). Taking the different visual stimulations
(unpleasant and neutral pictures) into account, there were also
four event-related conditions in total: unpleasant pictures and pla-
cebo (UP), neutral pictures and placebo (NP), unpleasant pictures
and control treatment (UC), and neutral pictures and control treat-
ment (NC). Each subject went through three sessions, each one
consisting of one placebo block and one control block. For further
details see [36]. After each block of pictures the experience of
unpleasantness was measured using a visual analogue scale
(VAS) ranging from 0 (no unpleasantness) to 100 (maximal imag-
ined unpleasantness). The behavioral placebo response was mea-
sured by subtracting the unpleasantness rating during the
control condition with the unpleasantness rating during the pla-
cebo condition.
In the present analysis we used data from the study on emo-
tional placebo described above [36] to try (1) to reproduce the
ﬁndings of a placebo-speciﬁc functional connectivity between
rACC and the vlPFC/lObfc for each subject and (2) to investigate
whether this functional relation relates to the degree of placebo ef-
fect (this analysis was not possible for the PET study because the
functional connectivity could only be performed on a group level).
The activity of the rACC was represented by a region of interest
(ROI) with a radius of 3 mm, centered on the voxel showing the
highest Z-score in rACC for the placebo responders in the study
of emotional placebo ([X Y Z] = [12 48 12]) (Fig. 1; [36]).
Firstly, we performed within-subject analysis. For each subject,
the activity, adjusted for session effects, was extracted for these
voxels in the placebo and the control blocks. The average activity
for each condition was subtracted from the adjusted activity for
each scan (mean correction). These activity values were then used
as condition-speciﬁc covariates of interest in a GLM implemented
in SPM99 (http://www.ﬁl.ion.ucl.ac.uk/spm) to generate regres-
sions between the rACC-ROI and the rest of the brain during placebo
condition (rPC) and control condition (rCC), in which the two treat-
ment conditions (placebo and control conditions) and the four
event-related conditions (UP, NP, UC and NC) weremodeled as con-
founding covariates. The functional connectivity effect we were
interested in this analysis was the regression between rACC-ROI
and orbitofrontal-/ventrolateral prefrontal cortex in both the pla-
cebo condition (rPC) and the control condition (rCC). We also stud-
ied the differences between the regressions in placebo condition
and control condition (rPC–rCC). The analysis was performed for
each subject, however, in two of the subject spikes were detected
in one of the three sessions, which therefore had to be removed.
Secondly, we performed a group analysis. In order to test
whether the functional relation between rACC and prefrontal cor-
tex in each subject (see above) was related to the degree of placebo
effect, a second-level random effect analysis was performed. In this
analysis the functional connectivity result for each subject was cor-
related with the reported placebo effect. This analysis will show
whether the functional connectivity between the rACC and the
vlPFC is most pronounced in the best placebo responders. Since
we were only interested in the functional relation between rACC
and vlPFC/lObfc a threshold of P-uncorrected < 0.001 was set for
reporting results in vlPFC and lObfc. Since one of the subjects’
behavioral data were lost only 14 subjects were enrolled in the sec-
ond-level analysis.
3. Results
3.1. Results from Study 1 – PET study on placebo and opioid analgesia
The results directly comparing the condition involving pain and
opioid treatment (i.e. opioid analgesia; POP) with pain and placebo
treatment (i.e. placebo analgesia; PPL) are shown below. Here, wetested whether ACC was more involved in opioid treatment condi-
tion, while the prefrontal areas (lObfc and vlPFC) were more in-
volved in the placebo condition. Moreover, we tested whether
the functional relation between rACC and the prefrontal regions
was more expressed in the placebo condition than in the opioid
condition. Analyses assessing the general placebo effect are pre-
sented elsewhere [34].
3.1.1. Opioid effect vs. placebo effect in pain (POP–PPL; Table 1)
The rACC (including the subgenual ACC) was signiﬁcantly more
activated in the opioid condition as compared with the placebo
condition. Likewise a region overlapping anterior insula and lObfc
was bilaterally more activated in this contrast. Upon inspection
this activation only marginally stretched into lObfc.
3.1.2. Placebo effect vs. opioid effect in pain (PPL–POP; Table 2)
The lObfc was signiﬁcantly more activated in the placebo condi-
tion as compared with the opioid condition (Fig. 2A). This activa-
tion was most pronounced in the right hemisphere in terms of
both the number of activated voxels and signiﬁcance scores (in
the left lObfc this activation did not reach signiﬁcance). However,
no formal comparison was made in the present dataset. The right
lObfc activation stretched up into the right vlPFC in a continuum
of activated voxels (Fig. 2B). The placebo-dependent activations
survived the exclusive masking indicating that they were true acti-
vations in the placebo condition rather than decreases in the opioid
condition.
3.1.3. Functional connectivity analysis (Table 3)
In this analysis the activity in rACC was co-varied with the rest
of the brain in order to characterize the connectivity between rACC
and PFC (see Section 2). rACC showed a signiﬁcant co-variation
with right and left lObfc and right vlPFC in the PPL condition. No
such effect was shown in the POP condition. When these two
regressors were compared it was shown that the rACC co-varied
signiﬁcantly more with the right vlPFC and lObfc in the placebo
condition than in the opioid condition (Fig. 2C and D).
3.2. Results from Study 2 – fMRI study of emotional placebo
A regression analysis was performed on the dataset involving
emotional placebo [36] in an attempt to reproduce the results
mentioned above indicating a placebo-speciﬁc functional relation
between rACC and vlPFC, and to test whether this connectivity cor-
related with the placebo response (see Section 2). This study has
previously shown a placebo-speciﬁc increase in rACC and several
regions of lObfc/vlPFC in the subtraction analysis (see further
[36]). The placebo response-related activity (UP–UC) in prefrontal
cortex also correlated with the behavioral placebo response in
the vlPFC (but not in the lObfc): [32 46 8] t = 5.89 (Fig. 3A and B;
[36]).
Fig. 2. Results from Study 1 in which a ﬁxed effect design was used. The lObfc (A) and the vlPFC (B) were more activated in placebo analgesia than in opioid analgesia (PPL–
POP). The rACC that was robustly activated also by opioid treatment co-varied with the vlPFC speciﬁcally in the placebo condition as compared with the opioid condition (C).
Adjusted rCBF activity indicates this relation for placebo (blue dots) but not for opioid (red dots) treatment (D).
Table 3
Analysis of the functional connectivity between rACC and vlPFC/lObfc in the placebo
and opioid conditions (Study 1). In the present analysis a ﬁxed effect design was used.
Region co-varying with rACC MNI coordinates t-value P-value
X Y Z[X Y Z] = [8 44 12]
Placebo analgesia (PPL)
62 P. Petrovic et al. / PAIN
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Ten of the 15 subjects showed a placebo-speciﬁc co-variation
between the rACC and the vlPFC/lObfc (see Supplementary Table 1).
In the second-order random effect analysis we probed whether this
functional relation correlated with the behavioral placebo effect.
The co-variation between rACC and vlPFC/lObfc tended to be most
expressed for the best placebo responders. No such effects were
observed in the control condition, and the co-variation between
rACC and vlPFC was shown to be signiﬁcantly stronger in the pla-
cebo condition than in the control condition (Fig. 3C and D).
4. Discussion
In the present study we extended the analysis of two previous
placebo studies in order to characterize a cognitive non-opioid
component of the placebo response. In the re-analysis of the PET
study on placebo analgesia [34] we observed that orbitofrontal cor-
tex and vlPFC were signiﬁcantly more activated during placebo
treatment than opioid treatment. Moreover, rACC displayed a func-
tional connectivity with these prefrontal regions speciﬁcally dur-
ing the placebo context. In the re-analysis of the fMRI study on
emotional placebo [36] we showed that the functional relation be-
tween rACC and vlPFC was associated with the degree of placebo
response.
In our original placebo analgesia study [34] we showed a neuro-
physiological correlate to previous behavioral studies indicating a
relation between the endogenous opioid system and placebo anal-
gesia [2,5–7,26]. The study showed a co-activated network in opi-
oid and placebo treatments including the rACC and the anterior
insula stretching into lObfc. Several other functional imaging stud-
ies have also indicated an involvement of rACC in the placebo
response [8,21,51,52,58]. Auto-radiographic and post-mortem
studies on humans, primates and rats [3,38,54], opioid receptorTable 2
Regions activated more by placebo than by opioid (remifentanil 0.5 lg/kg) during
pain (Study 1). In the present analysis a ﬁxed effect design was used.
Region MNI coordinates t-value P-value
X Y Z
Placebo analgesia vs. opioid analgesia (PPL–POP)
Right vlPFC* 36 52 4 4.43 <0.001
Right lObfc* 32 50 12 4.04 <0.001
Left lObfc* 24 52 18 3.07 ns
lObfc, lateral orbitofrontal cortex; vlPFC, ventrolateral prefrontal cortex; , indicates
regions surviving the exclusive masking procedure.binding studies [19,55,56], and blood ﬂow studies [1,10,15,53] on
human subjects indicate that ACC and insula have high concentra-
tions of opioid receptors. Altogether, these studies suggest that the
cortical opioid system is involved in mediating placebo analgesia.
Indeed, recent opioid receptor binding PET-studies have shown
an opioid response in the rACC during placebo analgesia [52,58].
Here, we show that opioid-rich areas in rACC and the anterior
insula were more extensively activated during opioid as compared
with placebo analgesia in line with the stronger analgesic effect in
the opioid condition. The activation of these areas was most likely
due to direct activation of opioid receptors by the exogenous opi-
oid (remifentanil). Conversely, the response was opposite in the
lObfc and the vlPFC, that is, a signiﬁcantly larger activation was ob-
served for placebo analgesia than opioid analgesia (Fig. 2A and B).
Raw data suggest that the binding potential in these prefrontal re-
gions is not as high as in ACC and insula [19,55,56] and they have
not shown increased activation by opioids in other imaging studies
[1,10,15,53]. The previously presented small opioid-induced lObfc
activation [34] was only observed on the border of an extensive in-
sula activation. In fact, the activation observed in lObfc may repre-
sent a smoothing effect of the data. Hence, although it has not been
shown whether lObfc/vlPFC has a lower concentration of opioid
receptors than ACC and insula, the prefrontal regions seem to be
involved in an opioid response to a lesser degree and may be more
important for other cognitive processes.Right lObfc/anterior insula 34 18 18 4.05 <0.001
Right lObfc 42 36 4 3.45 <0.001
Right vlPFC 36 52 6 3.90 <0.001
Left lObfc/anterior insula 24 14 18 4.45 <0.001
Left lObfc 28 36 14 4.40 <0.001
Opioid analgesia (POP)
– – – – – –
Placebo analgesia vs. opioid analgesia (PPL–POP)
Right vlPFC 40 54 0 3.16 0.001
Right lObfc 24 18 24 3.38 <0.001
Left lObfc 26 42 20 3.60 <0.001
rACC, rostral anterior cingulate cortex; lObfc, lateral orbitofrontal cortex; vlPFC,
ventrolateral prefrontal cortex.
Fig. 3. Results from Study 2 in which a random effect design was used. The placebo-dependent vlPFC activation in (UP–UC) correlated with the subjective placebo response
(rating of unpleasantness after placebo vs. control) (A and B). The placebo-speciﬁc rACC co-variation with the vlPFC correlated also with the subjective placebo ratings (C and
D).
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gest that the Obfc stores representations of the motivational value
for speciﬁc primary and secondary re-enforcers [18,22,23,30,31,
45,46]. The monitoring function involves representation of rewards
and expectations of upcoming rewards [30,31,41,45,46]. Contem-
porary models of Obfc function suggest that one key function of
this region is to signal the desirability of the expected outcomes
and hold those associations on-line until the motivational goal
has been achieved [42]. Moreover, prefrontal regions are important
in generating prediction errors in associative learning [47] and also
in pain processing [43].
Similar cognitive processes are involved in the placebo mecha-
nism [14]. Explicit expectations of a relative reward (i.e. the expec-
tation of pain relief) is a key function in the placebo analgesic
response [29,49,50], and treatment expectations correlate strongly
with the subsequent placebo response [39]. We therefore suggest
that the involvement of these prefrontal regions in placebo analge-
sia is related to the expectation of a treatment effect. A possible cri-
tique of this suggestion is that also the opioid analgesia condition
should contain treatment expectation, and therefore activate these
prefrontal regions to a similar degree. This is not challengeable in
the anticipation phase. However, we propose that neither the
expectation nor the error signals are the same during the two con-Table 4
Study of the functional connectivity between rACC and right vlPFC/lObfc that
correlated with the subjective placebo response (Study 2). In the present analysis a
random effect design was used.
Region co-varying with rACC MNI coordinates t-value P-value
X Y Z[X Y Z] = [12 48 12]
Placebo condition (rPC)
Right vlPFC/lObfc 28 54 4 3.36 0.003 ns
Right vlPFC/lObfc 34 54 8 2.73 0.009 ns
Left lObfc/lObfc 26 54 6 3.11 0.005 ns
Control condition (rCC)
– – – – – –
Placebo condition vs. control condition (rPC–rCC)
Right vlPFC/lObfc 28 52 4 4.36 <0.001
Left vlPFC/lObfc 26 50 6 3.25 0.003 ns
Left lObfc/lObfc 28 50 6 3.24 0.004 ns
rACC, rostral anterior cingulate cortex; lObfc, lateral orbitofrontal cortex; vlPFC,
ventrolateral prefrontal cortex; rCC, regression analysis during control condition;
rPC, regression analysis during placebo condition.ditions, since the opioid effect reduces the nociceptive input di-
rectly through opioid receptor activation while the placebo
condition does not. In other words the subjects still expect a pain
reduction during this condition, and will have a stronger error sig-
nal since the expectations do not match with the nociceptive input.
This suggests that the vlPFC/Obfc may be more active in the pla-
cebo condition (due to stronger expectations and larger error sig-
nal) in line with our ﬁndings.
An important question is whether this prefrontal activity pro-
cessing expectations and the error signal may also be involved in
inducing the placebo response. It has been shown that expecta-
tions have a major impact on visual perceptual experience
[17,44,57] on affective experience [28], and elaborating upon those
expectations requires the function of an intact Obfc [9,12]. More-
over, vlPFC and the lObfc have been implicated in top-down mod-
ulation of pain [4,33,40] including placebo analgesia [21,27,34,51],
depression [13] and experimental anxiety [20,24,25,32]. These
studies are in line with the idea that lateral ventro-orbital cortex
is involved in a general, and not only pain speciﬁc, cognitive pro-
cess that mediates modulation of pain and emotion [35].
A model for the mechanisms driving the placebo effect using
expectations and error processing is that this is a consequence of
Bayesian processing – as has been suggested for other perceptual
systems [16,17,57]. In that hypothesis perceptions derived from
external signals are a compromise between incoming signals and
the expectations in the system. It has been suggested that this type
of processing vastly increases efﬁciency of understanding the outer
world.
While lObfc and vlPFC may be involved in cognitive processes
driving the analgesic response during placebo, several receptor
and functional imaging studies have not found the same type of
an opioid-related involvement as shown for ACC and insula
[10,15,19,34,53,55,56]. Here, we suggest that prefrontal regions
may inﬂuence opioid systems in rACC – possibly through local
enkephalinergic inter-neurons. It has been suggested that such in-
ter-neurons may activate pyramidal projection neurons (through
opioid receptors) that in turn may regulate distant pain-modulat-
ing areas [48]. In line with our hypothesis, our regression data
showed the rACC co-varied with the lObfc/vlPFC in the placebo
analgesia condition but not in the opioid analgesia condition. The
same regions that co-varied with the rACC were also a part of
the regions that were speciﬁcally activated during placebo treat-
ment (PPL–POP) (Fig. 2B). We used the data from the study on
64 P. Petrovic et al. / PAIN

150 (2010) 59–65emotional placebo [36] to probe whether this functional relation
was directly related to the subjectively reported placebo response.
In that study we have previously shown that both the rACC and the
vlPFC correlate with the subjectively reported placebo effect and
treatment expectations [36]. In the present analysis we show that
the subjects who expressed the highest placebo response also had
the most reliable placebo-speciﬁc coupling between the rACC and
the vlPFC (Fig. 3C and D). Thus, we both replicated the placebo-spe-
ciﬁc functional relation between rACC and vlPFC and showed that
it is directly related to the placebo effect. The functional connectiv-
ity analysis in the emotional placebo study generalizes the idea
that prefrontal processes may interact with neuromodulatory sys-
tems in ACC to other areas than pain. Furthermore, the ﬁnding that
activity in rACC may be opioid dependent also in emotional pro-
cessing [37] suggests that the prefrontal cortex may drive opioid-
related modulatory systems in ACC during emotional placebo as
well.
There are several alternative interpretations of the present re-
sults. Firstly, it cannot be excluded that a placebo-like increase in
lObfc was masked in the opioid condition by pharmacologically in-
duced decreases in CBF that is either neural or vascular in origin.
Secondly, connectivity analysis does not show any causality – rACC
may as well control prefrontal activity. It is also possible that the
functional relation between rACC and lObfc represents a cognitive
bias to report pain scores in line with one’s prior beliefs. Moreover,
the lack of rACC–Obfc correlation in the opioid conditionmay be ex-
plained by other factors than a fulﬁlled expectation, e.g. it would
also be possible that a reduced level of consciousness or the height-
ened euphoric level during opioid condition attenuates this func-
tional relation. Finally, we did not measure expectations although
we used the reported decrease in unpleasantness during the condi-
tioning day (day 1) as a proxy to treatment expectations in [36].
Interestingly, this value correlated to the placebo effect day 2 in
both ACC and vlPFC. Finally, we only used open treatment in the
opioid condition and it would be interesting to study the prefrontal
involvement in open opioid treatment vs. hidden opioid treatment
[11] associated with different degrees of treatment expectation.
In conclusion, the present results show that placebo analgesia is
qualitatively different from an opioid drug response during pain.
These ﬁndings and the suggestion that drugs directly interfere with
the expectation pathway [11] indicate that a placebo response may
not be interpreted as a passive control to a speciﬁc drug effect, but
a highly active state in itself.
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